Evidence map›Paper›PMID 34540168›Full record

ArticleIranian journal of microbiology2021

Prevalence of multidrug-resistance and

Mehraj Ansari, Subhas Chandra Aryal, Ganesh Rai, Kul Raj Rai, Susil Pyakurel, Bina Bhandari, Anil Kumar Sah, Shiba Kumar Rai

Open access · diamondAbstract read
In one paragraph

Article in Iranian journal of microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Detection of blaBMC microbiology · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mehraj AnsariDepatment of Microbiology, Shi-Gan International College of Sciences and Technology, Kathmandu, Nepal.
Subhas Chandra AryalDepatment of Microbiology, Golden Gate International College, Kathmandu, Nepal.
Ganesh RaiDepatment of Microbiology, Shi-Gan International College of Sciences and Technology, Kathmandu, Nepal.
Kul Raj RaiDepatment of Microbiology, Shi-Gan International College of Sciences and Technology, Kathmandu, Nepal.
Susil PyakurelDepatment of Microbiology, Shi-Gan International College of Sciences and Technology, Kathmandu, Nepal.
Bina BhandariDepartment of Microbiology, Tribhuvan University, Kathmandu, Nepal.
Anil Kumar SahDepartment of Microbiology, Annapurna Research Centre, Kathmandu, Nepal.
Shiba Kumar RaiDepatment of Microbiology, Shi-Gan International College of Sciences and Technology, Kathmandu, Nepal.
Annapurna Neurological Institute and Allied Sciences · NPNepal Medical College Teaching Hospital · NPTribhuvan University · NP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesCarbapenems have been the choice of antibiotics for the treatment of infections caused by multidrug-resistant bacteria. The main objective of this study was to determine the prevalence of carbapenemase ( MATERIALS AND

methodsA total of 1,151 clinical samples were collected from the patients visiting Annapurna Neurological Institute and Allied Science and Annapurna Research Centre, Kathmandu, between June 2017 and January 2018. Antibiotic susceptibility testing (AST) was performed on the

resultsOf the total 1,151 clinical samples, 253 (22.0%) showed positive growth. Of them, 226 (89.3%) were identified as

conclusionThis study determined a high prevalence of MDR and carbapenem resistance among

Indexed as

bla IMPbla VIMCarbapenemaseCarbapenemsMultidrug resistance

Identifiers

PMID34540168
PMCPMC8416584
OpenAlexW3166104804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.